Novel Therapies in Development for Diabetic Macular Edema

Aniruddha Agarwal, Rubbia Afridi, Muhammad Hassan, Mohammad Ali Sadiq, Yasir J. Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for functional visual loss in the developed world. Laser photocoagulation has been used for decades in the treatment of DME. However, the advent of anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of DME. Three important anti-VEGF agents whose efficacy has been well established via phase III clinical trials include ranibizumab, bevacizumab, and aflibercept. However, even in the era of anti-VEGF therapies, there are some challenges that retina specialists have to confront in managing patients with DME. These include the need for frequent treatment and an unpredictable response to therapy. There is evidence to suggest that pathways other than the VEGF pathway may be playing a role in the development of DME. Thus, extensive research is focused on development of novel agents that target these pathways. This review focuses on novel therapeutic agents in development, which may be used as a monotherapy or in combination with anti-VEGF agents, for the management of DME in the future.

Original languageEnglish (US)
Article number75
JournalCurrent diabetes reports
Volume15
Issue number10
DOIs
StatePublished - Oct 22 2015

Fingerprint

Macular Edema
Vascular Endothelial Growth Factor A
Therapeutics
Phase III Clinical Trials
Light Coagulation
Diabetic Retinopathy
Retina
Lasers
Research

Keywords

  • Anti-VEGF
  • Clinical trials
  • DARPin
  • Diabetic macular edema
  • Diabetic retinopathy
  • Stem cell therapy
  • VAP-1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Agarwal, A., Afridi, R., Hassan, M., Sadiq, M. A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2015). Novel Therapies in Development for Diabetic Macular Edema. Current diabetes reports, 15(10), [75]. https://doi.org/10.1007/s11892-015-0652-z

Novel Therapies in Development for Diabetic Macular Edema. / Agarwal, Aniruddha; Afridi, Rubbia; Hassan, Muhammad; Sadiq, Mohammad Ali; Sepah, Yasir J.; Do, Diana V.; Nguyen, Quan Dong.

In: Current diabetes reports, Vol. 15, No. 10, 75, 22.10.2015.

Research output: Contribution to journalReview article

Agarwal, A, Afridi, R, Hassan, M, Sadiq, MA, Sepah, YJ, Do, DV & Nguyen, QD 2015, 'Novel Therapies in Development for Diabetic Macular Edema', Current diabetes reports, vol. 15, no. 10, 75. https://doi.org/10.1007/s11892-015-0652-z
Agarwal A, Afridi R, Hassan M, Sadiq MA, Sepah YJ, Do DV et al. Novel Therapies in Development for Diabetic Macular Edema. Current diabetes reports. 2015 Oct 22;15(10). 75. https://doi.org/10.1007/s11892-015-0652-z
Agarwal, Aniruddha ; Afridi, Rubbia ; Hassan, Muhammad ; Sadiq, Mohammad Ali ; Sepah, Yasir J. ; Do, Diana V. ; Nguyen, Quan Dong. / Novel Therapies in Development for Diabetic Macular Edema. In: Current diabetes reports. 2015 ; Vol. 15, No. 10.
@article{91f302996e83441880c0a224006174ba,
title = "Novel Therapies in Development for Diabetic Macular Edema",
abstract = "Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for functional visual loss in the developed world. Laser photocoagulation has been used for decades in the treatment of DME. However, the advent of anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of DME. Three important anti-VEGF agents whose efficacy has been well established via phase III clinical trials include ranibizumab, bevacizumab, and aflibercept. However, even in the era of anti-VEGF therapies, there are some challenges that retina specialists have to confront in managing patients with DME. These include the need for frequent treatment and an unpredictable response to therapy. There is evidence to suggest that pathways other than the VEGF pathway may be playing a role in the development of DME. Thus, extensive research is focused on development of novel agents that target these pathways. This review focuses on novel therapeutic agents in development, which may be used as a monotherapy or in combination with anti-VEGF agents, for the management of DME in the future.",
keywords = "Anti-VEGF, Clinical trials, DARPin, Diabetic macular edema, Diabetic retinopathy, Stem cell therapy, VAP-1",
author = "Aniruddha Agarwal and Rubbia Afridi and Muhammad Hassan and Sadiq, {Mohammad Ali} and Sepah, {Yasir J.} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "10",
day = "22",
doi = "10.1007/s11892-015-0652-z",
language = "English (US)",
volume = "15",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "10",

}

TY - JOUR

T1 - Novel Therapies in Development for Diabetic Macular Edema

AU - Agarwal, Aniruddha

AU - Afridi, Rubbia

AU - Hassan, Muhammad

AU - Sadiq, Mohammad Ali

AU - Sepah, Yasir J.

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/10/22

Y1 - 2015/10/22

N2 - Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for functional visual loss in the developed world. Laser photocoagulation has been used for decades in the treatment of DME. However, the advent of anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of DME. Three important anti-VEGF agents whose efficacy has been well established via phase III clinical trials include ranibizumab, bevacizumab, and aflibercept. However, even in the era of anti-VEGF therapies, there are some challenges that retina specialists have to confront in managing patients with DME. These include the need for frequent treatment and an unpredictable response to therapy. There is evidence to suggest that pathways other than the VEGF pathway may be playing a role in the development of DME. Thus, extensive research is focused on development of novel agents that target these pathways. This review focuses on novel therapeutic agents in development, which may be used as a monotherapy or in combination with anti-VEGF agents, for the management of DME in the future.

AB - Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for functional visual loss in the developed world. Laser photocoagulation has been used for decades in the treatment of DME. However, the advent of anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of DME. Three important anti-VEGF agents whose efficacy has been well established via phase III clinical trials include ranibizumab, bevacizumab, and aflibercept. However, even in the era of anti-VEGF therapies, there are some challenges that retina specialists have to confront in managing patients with DME. These include the need for frequent treatment and an unpredictable response to therapy. There is evidence to suggest that pathways other than the VEGF pathway may be playing a role in the development of DME. Thus, extensive research is focused on development of novel agents that target these pathways. This review focuses on novel therapeutic agents in development, which may be used as a monotherapy or in combination with anti-VEGF agents, for the management of DME in the future.

KW - Anti-VEGF

KW - Clinical trials

KW - DARPin

KW - Diabetic macular edema

KW - Diabetic retinopathy

KW - Stem cell therapy

KW - VAP-1

UR - http://www.scopus.com/inward/record.url?scp=84939638385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939638385&partnerID=8YFLogxK

U2 - 10.1007/s11892-015-0652-z

DO - 10.1007/s11892-015-0652-z

M3 - Review article

C2 - 26294336

AN - SCOPUS:84939638385

VL - 15

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 10

M1 - 75

ER -